Zinc Acetate · ZINC ACETATE 25 mg/1 · Capsule · Oral · Teva Pharmaceuticals USA, Inc.
NDC 57844-0215-52 · 250 CAPSULE in 1 BOTTLE · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | ZINC ACETATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Galzin — NDC 57844-0215-52," retrieved September 3, 2026, https://drugdashboards.com/drug/57844021552.
Free to cite with attribution — see how the data is put together.